Status:

ACTIVE_NOT_RECRUITING

Impact of COVID-19 on GU Disease

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Conditions:

COVID-19 Infection

Genitourinary Cancer

Eligibility:

All Genders

40+ years

Brief Summary

The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Discl...

Detailed Description

COVID-19 has a higher incidence in males compared to females and cancer patients have a higher risk of contracting COVID-19, and developing complications, and deteriorate more rapidly. COVID19 pandemi...

Eligibility Criteria

Inclusion

  • Subjects must be men and women 40 years of age or older
  • Subjects at risk or with GU cancer (Prostate, Bladder, Kidney)
  • Subjects with benign GU disorders ( BPH, UTI, Bladder infection and kidney stone)
  • Subjects must have a GU disease that requires clinic visit as determined by physician or healthcare provider following a telehealth appointment
  • Willing and able to provide blood and urine samples
  • Willing and able to complete a questionnaire to determine the COVID-19 symptoms.
  • Willing and able to sign informed consent form

Exclusion

  • Men and women below 40 years of age
  • Subjects do not have a GU disease

Key Trial Info

Start Date :

February 18 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 1 2026

Estimated Enrollment :

15240 Patients enrolled

Trial Details

Trial ID

NCT04761107

Start Date

February 18 2021

End Date

February 1 2026

Last Update

January 31 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Impact of COVID-19 on GU Disease | DecenTrialz